JPRN-UMIN000042698已完成未知
An ancillary study of (a randomized phase 2 study of TS-1 versus CDDP+VNR for adjuvant therapy in patients with non-small cell lung cancer)-exploratory study of cost-effectiveness - LOGIK1702-B
Clinical Research Support Center Kyushu0 个研究点目标入组 110 人开始时间: 2020年12月9日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Others,meta-analysis etc
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Nothing particular
研究者
相似试验
已完成
不适用
An ancillary study of "a randomized phase 2 study of TS-1 versus CDDP+VNR for adjuvant therapy in patients with non-small cell lung cancer(UMIN000027435)" - investigation of effect prediction bio-marker for adjuvant therapy.on-small-cell lung cancerJPRN-UMIN000027436Clinical Research Support Center Kyushu190
进行中（未招募）
不适用
A phase II randomised study to investigate the effects of Bevacizumab on cell proliferation and on pCR in patients with locally advanced operable breast cancer - NDEUCTR2005-005048-19-ITISTITUTO EUROPEO DI ONCOLOGIA120
已完成
不适用
A randomized phase II study investigating the addition of the specific cox-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC-IV epithelial ovarian fallopian tube or primary peritoneal carcinomasCancerISRCTN30851756VU University Medical Center (The Netherlands)200
进行中（未招募）
1 期
A randomized phase II study to investigate the addition of PD-L1 antibody MEDI4736 to a taxane-anthracycline containing chemotherapy in triple negative breast cancer.(GeparNuevo)MedDRA version: 20.1Level: LLTClassification code 10071115Term: Node-negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Patients with triple negative, early breast cancerMedDRA version: 20.0Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10006200Term: Breast cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10006201Term: Breast cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10071113Term: Node-positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10006199Term: Breast cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-002714-72-DEGBG Forschungs GmbH174
进行中（未招募）
不适用
EFFECT: A randomized phase II study to evaluate the EFficacy and impact on Function of two different doses of nab-paclitaxEl in elderly patients with advanCed breasT cancerPatients aged 65 years or older with histologically or cytologically confirmed breast cancer, locally recurrent and/or metastaticany estrogen/progesterone receptor statusHER2 receptor negative OR HER2 positive but with contraindication to anti-HER2 therapyMedDRA version: 14.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002707-18-ITFONDAZIONE SANDRO PITIGLIANI PER LA LOTTA CONTRO I TUMORI-ONLUS